Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 12/20 | 0.44 |
| ▸ | JAK1 | P23458 | 11/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26645058 | 0.90 | JAK2 (0.45) | JAK2JAK1MKNK1JAK3GPR119 | |
| SCHEMBL26645893 | 0.88 | MAPT (0.51) | JAK2JAK1MKNK1JAK3GPR119 | |
| SCHEMBL26645738 | 0.87 | MAPT (0.50) | JAK2JAK1MKNK1JAK3GPR119 | |
| SCHEMBL26645230 | 0.84 | BUB1 (0.47) | JAK2JAK1JAK3 | |
| SCHEMBL26645138 | 0.82 | GALR2 (0.48) | JAK2JAK1MKNK1JAK3 | |
| SCHEMBL26645717 | 0.79 | MKNK1 (0.55) | MKNK1GPR119 | |
| SCHEMBL26645516 | 0.76 | NR1H2 (0.46) | JAK2JAK1JAK3GPR119PTPN11 | |
| SCHEMBL30752610 | 0.75 | NR1H2 (0.46) | GPR119MAPK1 | |
| SCHEMBL30752612 | 0.75 | NR1H2 (0.46) | GPR119MAPK1 | |
| SCHEMBL30752613 | 0.75 | NR1H2 (0.46) | GPR119MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4519265-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023213882-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | WO | disclosed |